National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women.
Goss
Paul E
PE
Harvard Medical School, Boston, MA, USA. pgoss@partners.org
Richardson
Harriet
H
Chlebowski
Rowan
R
Johnston
Dianne
D
Sarto
Gloria E
GE
Maunsell
Elizabeth
E
Ingle
James N
JN
Alés-Martinez
José E
JE
D000730:Androstadienes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000517:prevention & control; D002170:Canada; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause; D011788:Quality of Life; D012107:Research Design; D018570:Risk Assessment
D000730:Androstadienes; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; C056516:exemestane